Cargando…

Post-transcriptional control of HIV-1 Gag expression

Detalles Bibliográficos
Autores principales:	Phalora, Prabhjeet, Mahiet, Charlotte, Malim, Michael, Swanson, Chad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848301/ http://dx.doi.org/10.1186/1742-4690-10-S1-P87

Ejemplares similares

Mov10, an APOBEC3G-interacting RNA-binding protein, inhibits HIV-1 infection
por: Arjan, Shetal, et al.
Publicado: (2011)

MR1: An unconventional twist in the tail
por: Phalora, Prabhjeet, et al.
Publicado: (2022)

Increasing the CpG dinucleotide abundance in the HIV-1 genomic RNA inhibits viral replication
por: Antzin-Anduetza, Irati, et al.
Publicado: (2017)

Dissecting the contribution of Gag domain in resistance development in HIV-1 patients failing ARV therapy
por: Carli, Ilaria, et al.
Publicado: (2013)

P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
por: Rolland, MM, et al.
Publicado: (2009)

Early presentation of HIV-1 KF11Gag and KK10Gag protective epitopes facilitate rapid CD8+ T cell activation and killing of virus infected cells
por: Kløverpris, HN, et al.
Publicado: (2012)

P20-12. Heterogeneity of Gag mutational pathways in primary HIV-1 subtype C infection
por: Novitsky, V, et al.
Publicado: (2009)

Expression of Gag and Pol from reconstructed HERV-Fc1, associated with multiple sclerosis
por: Nissen, Kari K, et al.
Publicado: (2011)

Post transcriptional regulation of HIV-1 gene expression by MATR3, PSF and Rev
por: Gharu, Lavina, et al.
Publicado: (2013)

P20-18. Diversity of Gag and Nef immunodominant regions in Brazilian HIV-1 B and F1 subtypes
por: Côrtes, FH, et al.
Publicado: (2009)

Gag-Vpu cross talk modulating HIV-1 envelope incorporation and infectivity in cell-type dependent manner
por: Gautam, Archana, et al.
Publicado: (2012)

P16-11. HLA-B57/5801 induces preferential CD27 expression on HIV-Gag but not Nef specific central memory CD8+T cells controlling HIV
por: Xie, J, et al.
Publicado: (2009)

Characterisation of a spumavirus Gag protein
por: Goldstone, David C, et al.
Publicado: (2013)

A pantothenate suxotroph of BCG rxpressing Gag confers enhanced HIV-specific immunogenicity compared to wildtype and perfingolysin expressing strains
por: Chetty, S, et al.
Publicado: (2012)

Lymphoproliferative responses to HIV-1 Gag p24 antigen and mitogens in HIV-1 subtype CRF01_AE infected Thai patients and HIV-1 seronegative donors
por: Chuenchitra, Thippawan, et al.
Publicado: (2006)

The recognition of HIV-1 consensus group M Gag and Nef peptide reagents in mono- and multi-clade epidemics: implications for HIV vaccine design
por: Zembe, L, et al.
Publicado: (2012)

Placement of p6pol between tandem repeat HIV-1 protease domains reduces Gag cleavage efficiency
por: Chou, Tin-An, et al.
Publicado: (2013)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
por: Singh, V, et al.
Publicado: (2012)

Immunodominance and viral ditness in Gag may contribute to differential viral control in HLA-B*7 supertype individuals acutely infected with HIV-1C
por: Gounder, K, et al.
Publicado: (2012)

P02-10. Plant expression of chimeric Gag/gp41 virus-like particles as a mucosally-targeted subunit vaccine against HIV-1
por: Kessans, SA, et al.
Publicado: (2009)

P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
por: Stutz, H, et al.
Publicado: (2009)

Dynamics and frequency of Gag transmitted polymorphisms in Zambia
por: Schaefer, M, et al.
Publicado: (2012)

Characterization of the barrier conferred by type I interferon on the early steps of HIV-1 infection in primary cells
por: Goujon, Caroline, et al.
Publicado: (2011)

Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 gag
por: Qiu, Jian-Tai, et al.
Publicado: (2006)

P16-16. Gag and Nef specific T-cell responses in HIV-1 infected long-term non-progressors in Uganda
por: Kyosiimire-Lugemwa, J, et al.
Publicado: (2009)

P10-10. HIV-1 Gag virus like particles pseudotyped with CD40 ligand to stimulate innate immune responses
por: Köstler, J, et al.
Publicado: (2009)

Characterization and quantitation of fluorescent Gag virus-like particles
por: Gutiérrez-Granados, Sonia, et al.
Publicado: (2013)

Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
por: Ondondo, Beatrice, et al.
Publicado: (2006)

P16-45. High avidity CD4+ T cell response directed to an immunodominant Gag epitope in HIV controllers: an ANRS EP36 study
por: Vingert, B, et al.
Publicado: (2009)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

P09-09. Impact of immune-driven sequence variation in HIV-1 subtype C Gag-Protease on viral fitness and disease progression
por: Wright, JK, et al.
Publicado: (2009)

Limited evidence for alterations in Gag-mediated HIV replication capacity over the course of the North American epidemic (1979-present)
por: Cotton, L, et al.
Publicado: (2012)

Immune response after vaccination of HIV infected individuals receiving HAART with overlapping gag peptides pulsed on autologous cells
por: Kløverpris, H, et al.
Publicado: (2012)

P16-49. Broad types of cytokines secreted by Gag-specific T cells from HIV infected patients on HAART
por: Montes, M, et al.
Publicado: (2009)

A prime-boost immunization with rBCG expressing HIV-1 Gag, RT and gp120 and SAAVI MVA-C elicits immune responses in blood and MALT of rhesus macaques
por: Chege, GK, et al.
Publicado: (2012)

Evolution of a Species-Specific Determinant within Human CRM1 that Regulates the Post-transcriptional Phases of HIV-1 Replication
por: Sherer, Nathan M., et al.
Publicado: (2011)

P16-12. Relative dominance of Gag-specific cytotoxic T lymphocytes is associated with viral load inversely in HIV-1 clade B' infected Chinese
por: Jia, M, et al.
Publicado: (2009)

P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses
por: Wild, J, et al.
Publicado: (2009)

Immunodominant Anti-Gag SLYNTVATL Responses in HIV-patients With More Than Five Years of HAART-induced Undetectable Plasma Viremia
por: Remenar, Anica, et al.
Publicado: (2005)

P17-24. Interfering overlapping epitopes contribute to the subdominance of an HLA-A2-restricted HIV Gag-specific epitope
por: Kan-Mitchell, J, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_kjafnq7o4alqn6mhfjpm0l0nch